DNA ampli®cation is a readily measurable indicator for genome destabilization. Contrary to normal senescing cells, those of most immortal or transformed cell lines are karyotypically unstable and permissive for ampli®ca-tion. Permissivity for ampli®cation can be generated by gene products of several DNA tumor viruses whereby their interaction with the tumorsuppressor protein p53 is important. p53 is the major protein involved in check point control of DNA damage. Polyomavirus large T antigen is also involved in immortalization and transformation of cells but it does not interact with p53. We, therefore, examined whether this protein could still make the non-permissive cell line REF52 permissive for gene ampli®cation. To this end REF52 cell lines were constructed which conditionally expressed the wild type polyomavirus large T antigen or a mutant form unable to bind the retinoblastoma protein. Using the inhibitor of de novo pyrimidine biosynthesis, phosphonoacetyl-L-aspartate (PALA), as selective agent we found that PALA resistant cells arise with a frequency of about 5610 75 and that the interaction of polyomavirus large T protein with the retinoblastoma protein or another related pocket protein is important for this to occur. PALA resistant cells have an increased number of chromosomes and dicentric chromosomes which are considered as starting point for DNA structures characteristic for ampli®ed DNA. Such structures were indeed found with the help of uorescence in situ hybridization. PALA resistant cells appear normal with respect to p53. Our data indicate that PALA induces a G 1 block which can be partially overcome by polyomavirus large T protein by its interaction with E2F-pocket protein complexes providing further evidence that these complexes are downstream targets of p53.
Introduction
Genomic instability is a characteristic of tumor cells and of most immortal cell lines. It ranges from aneuploidy to various chromosomal aberrations including DNA ampli®cation. The latter chromosomal abnormality is not only characteristic for most tumor cells and is responsible for the frequent development of drug resistance in cancer treatments, but it is also often used as a relatively easily measurable indicator of genomic instability in experimental systems (for recent reviews see Hamlin et al., 1991; Stark, 1993; Wintersberger, 1994; Chernova et al., 1995) . Normal cells (in particular normal diploid human cells) have a well functioning feedback or checkpoint system (for reviews see Lane, 1992; Hartwell, 1992; Hartwell and Kastan, 1994; Kaufmann and Paules, 1996) which prevents the multiplication of cells carrying genomic abnormalities. These cells are not permissive for DNA ampli®cation Tlsty, 1990; Wright et al., 1990) , rather the checkpoint mechanism leads to cell cycle arrest and eventually to apoptosis of cells which have suered from DNA damage. This is not true for many immortalized cells, for transformed cells and for cells derived from tumors. Such cells are permissive for ampli®cation, they can, therefore, not be used to study the mechanisms that make cells permissive for DNA ampli®cation (Perry et al., 1992) . Senescing cells, on the other hand, are problematic as they usually exhibit low transfection eciency and have a ®nite life span. Fortunately, there is one cell line, the rat embryo ®broblast cell line REF52, which, despite an inde®nite growth potential, is not permissive for DNA ampli®cation. These cells were previously used to study conditions which make cells permissive for ampli®cation (Perry et al., 1992; Ishizaka et al., 1995) .
The tumorsuppressor protein p53 has been shown to play an important role in the checkpoint control elicited by DNA damage (Yin et al., 1992; Livingstone et al., 1992 ; see also the review by Cox and Lane, 1995) or by a shortage of DNA synthesis precursors (Linke et al., 1996) . The latter situation arises, for instance, after addition of phosphonoacetyl-L-aspartate (PALA) to cell cultures. PALA inhibits a complex of enzymes, encoded by the CAD gene, which catalyses the ®rst three steps of de novo pyrimidine biosynthesis. DNA strand breaks or a de®ciency of precursors bring about an increase in the amount of p53 which acts as a transcription factor to induce the synthesis of a variety of proteins (Cox and Lane, 1995) , among which there is p21 (also called WAF1, CIP1, Sdi-1). p21 is an inhibitor of cyclin dependent kinases (CDKs) and of the replicative function of PCNA. It causes a G 1 arrest by inhibiting the phosphorylation of pRB (which itself is a prerequisite for progression through G 1 and into the S phase) and it inhibits DNA replication in S phase (but not DNA repair) by its interaction with PCNA (Waga et al., 1994; Shivji et al., 1994) . Proteins coded by several DNA tumor viruses (adenovirus E1B 55k protein, SV40 large T antigen, human papilloma virus protein E6) were found to bind p53 and to cause its inactivation or destruction (for a review see Shen and Shenk, 1995) . Such viral proteins or mutations in p53 make cells permissive for DNA ampli®cation and it is assumed that this reaction contributes to the transforming and immortalizing activity of these viruses (Perry et al., 1992; White et al., 1994) . There is one interesting exception: polyomavirus does immortalize and transform cells but none of the proteins encoded by polyomavirus DNA interacts with p53 (see the review by Pipas, 1992) . On the other hand, polyomavirus large T antigen (PyLT) shares with SV40 large T antigen, adenovirus E1A protein and papillomavirus protein E7 the capacity to bind the tumorsuppressor protein pRB and the related pocket proteins p107 and p130 (reviewed by Moran, 1993; La Thangue, 1994; Nevins, 1994) . These proteins are inhibitors of a family of transcription factors called E2F. The inhibitory activity of the pocket proteins appears to be relieved by phosphorylation through speci®c cyclin/CDK combinations, thereby allowing E2F to become active and to induce transcription of G 1 and S phase-speci®c genes. Considering that one of the major events following an increase of p53 is the synthesis of p21, which results in an inhibition of CDKs thus blocking the release of pocket proteins from E2F and thereby transcription of G 1 and S phase speci®c genes, it is assumed that this is the major way by which p53 exerts its eect (Cox and Lane, 1995) . The complexes of E2F and pocket proteins accordingly appear to be downstream targets of p53 mediated checkpoint control (reviewed by Kouzarides, 1995) . As these complexes are dissociated by the DNA tumor virus gene products mentioned above, including PyLT, it is pertinent to ask whether PyLT, although incapable of interfering with p53, can make cells permissive for gene ampli®cation and whether this depends on the potential of the viral protein to interact with the pocket proteins. We found that wild type PyLT, but not the mutant defective in pRB binding, does allow REF52 cells to by-pass the PALA induced check point and to amplify the CAD gene leading to PALA resistance. Ampli®ed structures resemble those found frequently in gene ampli®cation resulting from a direct involvement with the function of p53. Still the PALA resistant cells that developed in our experiments appear normal with respect to p53. Our results, therefore, lend support to the assumption that complexes of pRB and/or other pocket proteins with transcription factor E2F, the cellular constituents with which PyLT has to interact in order to exhibit its eect, are downstream targets of the p53-induced checkpoint control.
Results
Construction and characterization of REF52 cells which conditionally express wild type or mutant PyLT REF52 cells were transfected with a plasmid carrying the information for PyLT under the dexamethasoneinducible MMTV promoter (Ogris et al., 1992) and a plasmid carrying the neo gene under the constitutive SV40 promoter providing resistance to Geneticin. Control cells received a plasmid carrying only the neo gene but no polyomavirus information. The mutant form of PyLT had an amino acid substitution at position 146 where a glutamic acid residue within the LXCXE motif of the binding region for pocket proteins was replaced by an aspartic acid residue. This amino acid change abolished the interaction of PyLT with the pocket proteins (Larose et al., 1991) . Stably transfected clones were selected with Geneticin and examined for the dexamethasone-inducible expression of PyLT. One clone each of REF52 cells expressing wild type PyLT (REF52-LT8) and mutant PyLT (REF52-LTRB 7 12) was chosen for further studies, together with a control clone expressing only the neo gene. Figure 1 shows the inducibility of wild type and mutant PyLT in the selected clones as well as the capacity of the wild type but not the mutant protein to bind pRB and p107. Several properties of these clones were compared with those of REF52 cells. These include plating eciency, population doubling time and sensitivity to PALA. All these characteristics were found to be quite similar for the dierent cells (Table 1) excluding the possibility that the transfection procedure led to the selection of cell clones with signi®cantly altered properties.
Selection of PALA resistant cell clones
The four cell types, parent REF52 cells, REF52 cells transfected with the neo gene only and with the neo gene and wild type or mutant PyLT, were grown in the presence of six times the lethal dosis 50 of PALA (see Table 1 ) and in the absence or in the presence of 1 mmol/l of dexamethasone for induction of PyLT. Only cells expressing wild type PyLT gave rise to the appearance of PALA resistant clones at a frequency of around 5.5610 75 ( 
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PyLT-induced DNA amplification P Stiegler et al in agreement with several previous reports concerning cells not permissive for DNA ampli®cation (Tlsty, 1990; Wright et al., 1990) .
Characterization of PALA resistant REF52 cells
Resistance to PALA is the result of ampli®cation of the CAD gene. Gene ampli®cation can principally occur in either one of two ways, namely by chromosomal aberrations leading to the appearance of double minute chromosomes or of homogeneously staining regions, both of which carry multiple copies of the particular gene whose ampli®cation was selected for by the drug. Alternatively, cells with an aneuploid karyotype that have acquired supernumerary chromosomes carrying the gene in question might have been selected. As the ®rst mentioned process requires interference with p53 (Livingstone et al., 1992; Yin et al., 1992; Nelson and Kastan, 1994) and as PyLT is known not to combat with this protein, we thought it more likely that the latter mechanisms, aneuploidization, is responsible for the appearance of PALA resistant cells in response to the activity of PyLT. We, therefore, determined the chromosome number of several PALA resistant clones and compared it with that of normal REF52 cells, as well as with that of cells transfected with the neo gene only or with mutated PyLT. The results ( Table 3 ) clearly show that our expectation was true: PALA resistant clones, but only those, had a signi®cantly higher number of chromosomes than the parent REF52 cells. However, upon closer inspection of the karyotype of PALA resistant clones ( Figure 2 ) it became clear that there was not only a higher number of chromosomes but there were chromosomal aberrations visible, in particular dicentric chromosomes, which are thought to be responsible for the generation of ampli®ed genes through bridge breakage fusion (BBF) cycles (reviewed by Stark, 1993) . We have, therefore, carried out¯uorescence in situ hybridization (FISH) experiments to analyse ampli®ed CAD gene structures in more detail and indeed found many examples of structures ( Figure 3 ) as they were repeatedly shown to be characteristic for ampli®ed genes originating through interference with the p53-mediated checkpoint control Windle et al., 1991; Ma et al., 1993; Toledo et al., 1993) .
Are PALA resistant cells devoid of normally functioning p53?
As it was possible that CAD gene ampli®cation only occurred in cells in which a permanent change in p53 took place as a consequence of the expression of PyLT, we tested the status of p53 in PALA resistant clones and obtained evidence that p53 is normal in several respects: Using two dierent antibodies which allow to distinguish between wild type p53 and p53 mutants exhibiting characteristic changes in tertiary structure of the protein (Gannon and Lane, 1991; Milner, 1995) we obtained evidence that the p53 synthesized in PALA resistant cells is most likely wild type; it is readily detected by antibodies seeing the wild type configuration of the protein but not by an antibody speci®c for the structure of mutants (Figure 4) . Furthermore, PALA resistant cells responded normally to u.v. irradiation; a high percentage of cells accumulated in the G 1 phase of the cell cycle just like REF52 cells but unlike SV40 transformed cells in which p53 is inactivated by SV40 LT protein (Figure 5a ). The amounts of p53 increased in PALA resistant cells upon u.v. irradiation like in normal cells (Figure 5b ). Attempts to see a similar increase of p21 as a consequence of the u.v.-induced increase in p53 failed because logarithmically growing PALA resistant cells exhibited already high levels of p21. A similar observation was made with MRC5 cells, a senescing cell line of human ®broblasts. We do not know the reason for this eect, however, it is known that p21 can be induced by a p53-independent mechanism and is high in senescing cells (Rubelj and Pereira-Smith, 1994) . PALA resistant cells, having gone through two strong selections and being aneuploid may resemble such a situation. Despite this, we conclude that PALA resistant cells selected by the function of PyLT are normal with respect to p53 and this is reinforced by experiments described below.
How does PyLT make REF52 cells permissive for DNA ampli®cation?
Considering that no PALA resistant cells arose when a mutant of the viral protein which is not able to bind to pRB and the other pocket proteins was synthesized in REF52 cells, it is likely that binding of PyLT to a pocket protein followed by removal of the pocket protein from complexes containing transcription factor E2F was responsible for the eects observed. As induction of PyLT and addition of PALA was done in cell cultures growing in the presence of 10% serum, we examined the eect of the production of PyLT in growing REF52 cells on complexes formed on binding motifs for E2F using mobility shift assays. Much to our surprise, we did not observe any changes in the complexes whether wild type PyLT or the mutant form or no viral protein was produced in the cells ( Figure  6a ). With the use of a speci®c antibody we found that the pocket protein primarily present on such complexes is p107; addition of an anti-p107 antibody almost completely supershifted the band of the complexes. A similar absence of destruction of E2F complexes forming with extracts from replicating cells was observed when we used extracts from growing COP8 cells. These are mouse cells which are transformed by a replication defective polyomavirus and which produce large amounts of all three T antigens. Quite in contrast, when extracts from SV40 transformed cells were employed, complexes were completely dissociated to free E2F. Thus, PyLT signi®cantly diers from SV40 LT and adenovirus E1A protein in that it does S labeled methionine plus cysteine and proteins were extracted, immunoprecipitated with an antibody against wild type p53 (pAB 122) or with that speci®c for the mutated conformation of the protein (pAB 240). Immunoprecipitates were separated by acrylamide gel electrophoresis and p53 was visualized by¯uorography
PyLT-induced DNA amplification P Stiegler et al not dissociate E2F complexes when extracts from replicating cells are used. As shown in Figure 1 , wild type PyLT present in such cells does bind to p107 and to pRB, while the 146D mutant does not, con®rming a previous report (Larose et al., 1991) . In another control we validated earlier observations from this laboratory (Ogris et al., 1993) which showed that PyLT does dissociate complexes formed on an E2F motif if the cell extracts containing the viral protein originated from serum starved, quiescent cells. As shown in Figure 6b these complexes contain p130; they are almost completely supershifted by anti-p130 antibody but not by anti-p107 antibody. Taking all these observations into account it is most likely that PyLT interferes with pocket proteins (p130 and possibly pRB) present in arrested cells. Such cells are expected to emanate in our cell cultures as a consequence of the addition of PALA and through the activity of p53. That p53 is indeed functional in the presence of PyLT is demonstrated by the experiment shown in Figure 7 .
Here the amounts of p21 present in extracts of cells incubated with PALA in the absence or presence of PyLT were determined by immunoblotting. As Mobility shift experiments were carried out as described in Materials and methods using the E2F motif of the murine TK promoter as labeled oligonucleotide. Proteins in extracts of growing cells were used. REF52 cells did not produce a viral protein and represent the control, COP8 cells are polyomavirus transformed murine C127 cells which produce large amounts of all three tumor antigens. SVMK cells are SV40 transformed mouse kidney cells, producing SV40 large and small T antigen. SD15 is an anti-p107 antibody giving rise to a supershift of p107-containing complexes. (b) LT dissociates complexes present in quiescent cells. These complexes contain the pocket protein p130 as they are supershifted by antibody speci®c for this protein (C-20) while no supershift is obtained with anti-p107 antibody the viral protein; additional expression of PyST signi®cantly increased this percentage (Ogris et al., 1992) . We now found that treatment of either REF52-LT8 cells or 3T3LT with PALA in the presence of 10% serum also led to a complete G 1 arrest. Only if wild type PyLT is produced at the same time can a fraction of these cells escape the replication block and move into S phase. We assume that PALA resistant cells arose from this small subpopulation of REF52 cells.
Discussion
The rat embryo ®broblast cell line REF52, like normal human diploid ®broblasts, is not permissive for DNA ampli®cation (Perry et al., 1992) . These cells react to DNA damage or insucient supply of ribonucleotides and deoxyribonucleotides, a condition created by various inhibitors of nucleotide synthesis, by G 1 arrest. Central in these reactions is the tumorsuppressor protein p53 which accumulates under those conditions and causes the induction of a variety of genes (Cox and Lane, 1995) . Important among these is the CDK inhibitor protein p21. Mutation of p53 or interference with its activity, a condition generated by proteins coded by several DNA tumor viruses, makes cells permissive for DNA ampli®cation (Perry et al., 1992; White et al., 1994) . DNA ampli®cation is seen as one indication for genome destabilisation which itself is a characteristic of immortalized and transformed cells.
PyLT can contribute to immortalization and transformation of cells but, unlike SV40 LT antigen or papillomavirus E6 protein, it does not directly interfere with p53. We, therefore, asked whether PyLT might still lead to genome destabilization and gene ampli®cation and found that this is indeed the case as long as the amino acid sequence decisive for the interaction of PyLT with pRB and the other pocket proteins is intact. Cells selected for the presence of an ampli®ed CAD gene by addition of PALA have higher chromosome number and in addition show the same structures of ampli®ed genes as previously observed in several other cases Windle et al., 1991; Ma et al., 1993; Toledo et al., 1993) . The PALA resistant cells appear normal with respect to p53. It is likely therefore, that PyLT acts downstream of p53 at the level of the pocket proteins which regulate the activity of transcription factor E2F (Chernova et al., 1995; Kouzarides, 1995 (Ogris et al., 1992) . We now found that treatment of either REF52-LT8 cells or 3T3LT with PALA in the presence of 10% serum also led to a complete G 1 arrest. Only if wild type PyLT is produced at the same time can a fraction of these cells escape the replication block and move into S phase. This scenario thus would be analogous to the one very recently described by Stark and coworkers (Poupon et al., 1996) . These authors found that concentrations of PALA which did not lead to a complete G 1 arrest stimulated gene ampli®cation. Since the inhibitor concentrations used in our work did lead to complete replication block in the absence of wild type PyLT as evidenced by the absence of any PALA resistant clones in all the control experiments, it is the viral protein which allows some cells to overcome the block and to become permissive for ampli®cation. Hence, although not directly interacting with p53, PyLT still allows cells to overcome a p53-induced cell cycle block by interfering with a reaction downstream of p53. The inhibitory activity of p53-induced p21 on CDKs is without eect when PyLT can remove the pocket protein and thus relieve its inhibitory action on transcription factor E2F. PALA-resistant cells, thus, likely arise from the small fraction of cells escaping the replication block. These cells then move into S phase but due to the absence of a sucient supply of precursors soon cease DNA replication resulting in the accumulation of single-stranded regions which may give rise to double strand breaks and, hence start BBF cycles. As much as this could explain the appearance of dicentric chromosomes and of ampli®cation structures like those shown in Figure 3 , it is much less clear how aneuploidy arises. Extensive overreplication is highly unlikely in the presence of PALA. It is interesting that we found cells which were aneuploid but did not show other detectable chromosomal aberrations as if REF52 REF52 +uv REF52 REF52 +PALA REF52-LT8 REF52-LT8 +PALA REF52-LT8 +PALA +Dexa
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Figure 7 p21 is normally induced in REF52 and REF52-LT8 cells by u.v. irradiation (18 J/m 2 ; extracts were prepared 8 h thereafter) or by treatment with PALA (six times the lethal dosis 50 for 9 h). PyLT (induced in REF52-LT8 cells by addition of 1 mmol/l of dexamethasone) does not interfere with the induction of p21 in PALA treated cells. Western blots were probed with anti-p21 antibody (H-164 from Santa Cruz). A control with human cells (MRC5) proves that this antibody speci®cally detects p21 aneuploidization were the primary karyotypical change occurring. In this regard it is worth mentioning that recent reports suggest a role of p53 also at the G 2 /M checkpoint (Cross et al., 1995; Agarwal et al., 1995) although the protein appears to control the cell cycle predominantly in G 1 . Downstream targets of p53 at the G 2 control are not known so far. On the other hand, the observations that pRB interacts with several proteins potentially involved in mitosis Zhu et al., 1995; Thomas et al., 1996) as well as the fact that pRB exhibits M phase-speci®c binding to a protein phosphatase type 1 which may be related to cell cycle-speci®c changes of the phosphorylation status of pRB (Durfee et al., 1993) is of particular interest. It is possible that PyLT interferes with such functions of pRB resulting in failures during mitosis. At any rate it has to be assumed that these changes occur before a PALA-induced G 1 arrest. PyLT might then allow some of the arrested aneuploid cells to get out of this block.
While there is ample support for the importance of an interaction of SV40 LT antigen with p53 in making REF52 cells permissive for ampli®cation, other studies indicate that the amino terminal portion of the protein, lacking the p53 interaction site, can overcome a p53-mediated growth arrest (Quartin et al., 1994) and induce genomic instability (Woods et al., 1994) . Similar ®ndings were reported for human papilloma virus E7 protein (Vousden et al., 1993; Hickman et al., 1994; Demers et al., 1994; Szebos et al., 1994) . On the other hand, adenovirus E1A protein was shown to convert REF52 cells to the permissive state only when mutant Ras protein was present at the same time (Perry et al., 1992) and papillomavirus E7 protein was found to induce aneuploidy in PALA treated normal human ®broblasts but due to massive cell death cell lines could only very rarely be selected (White et al., 1994) . We do not have a de®nitive explanation for these dierences between the dierent viral proteins but it may be related to subtle dierences between the viral proteins in their capacity to dissociate E2F pocket protein complexes. We observed that PyLT dissociates E2F pocket protein complexes only in arrested ®broblasts but not in growing ones, although the viral protein produced in growing cells binds to p107 and the other pocket proteins. As yet we do not have an explanation for this eect, however, a similar, but not identical, situation was observed with papillomavirus E7 protein which was found to dissociate p107 containing complexes only if they did not at the same time carry cyclin A, i.e. E7 dissociated p107 complexes in G 1 but not in S phase (Zerfass et al., 1994) . The recent observation (Ikeda and Nevins, 1993 ) that E1A protein may have two separate functions in its activity towards pocket proteins, one being the capacity to bind the protein, the other one the dissociation of complexes, might be relevant in this regard. If the same holds for other tumor virus proteins, one could assume that dierent viral proteins have varying eects on the dierent complexes of the pocket proteins. Alternatively, PyLT produced in arrested and in growing cells might dier in that part of the protein which is required for the dissociation of the complexes. This dierence may lie in posttranslational modi®cation, possibly in the phosphorylation status, of the protein.
Experiments are being carried out to test these possibilities.
Materials and methods

Cell culture
REF52 and Swiss 3T3 cells were maintained in Dulbecco's modi®ed Eagles medium (DMEM) supplemented with 10% fetal calf serum (FCS), penicillin (60 mg/ml) and streptomycin (100 mg/ml) in a 7.5% CO 2 atmosphere. Stable REF52 lines, inducibly expressing wild type PyLT (REF52-LT8) and mutated PyLT (REF52-LTRB 7 12) were generated by calcium phosphate cotransfection of the plasmid pSV2neo and pMMTV-PyLT or pMMTV-PyLTmut respectively (Ogris et al., 1992; Mudrak et al., 1994) , and subsequent selection in the presence of Geneticin (600 mg/ml of medium). Time determination of population doubling (PDL) was done as described previously (Otto et al., 1989) . u.v. treatment was performed in a Stratalinker, exposing cells (16PBS washed) to 18 J/m 2 , followed by incubation in complete DMEM for indicated periods. Cell cycle distribution analysis was performed by¯ow cytometry (FACS) as described previously (Ogris et al., 1992) .
Immunoprecipitation, GST pull down experiments and immunoblots
The inducibility and quantity of PyLT and PyLTmut expression in stable cell lines was checked by incubating 10 6 cells with 1 mM Dexamethasone for 16 h and subsequent protein extraction in buer A (20 mM Tris.Cl [pH 8.0], 100 mM NaCl, 1 mM EDTA, and 0.5% NP40) as described elsewhere (Adamczewski et al., 1993) . Lysates were either analysed in a direct immunoblot or used for GST pulldown experiments with GST, GST-pRB 379 ± 928 and GST-p107 259 ± 936 as described previously (Karlseder et al., 1996) . PyLT and PyLTmut were then detected by a chemiluminescence reaction (Rennaissance NEN) using a freshly prepared rabbit polyclonal antiserum raised against PyST with the help of a bacterial fusion protein (Pallas et al., 1986) . This antibody reacts with the N-terminal portion of PyLT which is identical with the PyST protein. p53 status was checked by immunoprecipitations with monoclonal antibody pAB 122 (ATCC TIB 116) against wild type p53 and pAB 240 which is speci®c for the p53 in mutated conformation (Gannon and Lane, 1991) . Subconuent cells were labeled with 80 mCi per ml of Translabel (ARC incorporated) for 90 min and proteins were extracted and subjected to immunoprecipitation as described elsewhere (Adamczewski et al., 1993) . p53 steady state and u.v.-induced levels were analysed in immunoblots with pAB122 followed by a chemiluminescence reaction. For immunoblotting of p21 the anti-p21 antibody H-164 (Santa Cruz) was used. In all immunoblot experiments 20 mg of protein were used per lane.
Electrophoretic mobility shift assay (EMSA)
Cellular lysates were prepared as for immunoprecipitation and 10 mg of protein were used for EMSA with the oligonucleotide for the E2F site of the murine thymidine kinase promoter as described previously (Ogris et al., 1993) . E2F complexes containing p107 or p130 were supershifted by incubating the reaction with the p107 speci®c monoclonal antibody SD15 (Dyson et al., 1992) or with the p130 speci®c antibody C-20 (Santa Cruz).
Clonogenic assay
Quanti®cation of gene ampli®cation potential was done as described previously (Otto et al., 1989) . Plating eciency was determined by seeding 10 3 cells in 150 mm dishes and ®xing, staining and counting the colonies after 2 weeks. LD 50 , the drug concentration allowing 50% survival was determined by seeding 10 4 cells in 30 mm dishes and growing these with dierent PALA concentrations until the cells on the control plate were nearly con¯uent. The cells were trypsinized and counted to calculate the LD 50 . Ampli®cation frequency was expressed as the number of PALA resistant colonies at 66LD 50 relative to the plating eciency. PALA was obtained from the Drug synthesis and Chemistry Branch, Division of Cancer Treatment, National Cancer Institute.
Slide preparation
Cells from subcon¯uent cultures were incubated with colcemid (0.4 mg/ml) for 2 h, trypsinized, incubated in 0.75 mM KCl for 15 min and ®nally ®xed in methanol:acetic acid (3:1). They were then spread onto slides and stored at 7208C in N 2 -enriched atmosphere. For karyotypic analysis DAPI (2 mg/ml) stained metaphases were examined.
Fluorescence in situ hybridisation (FISH)
The FISH analyses of the CAD gene were performed with CAD 1 and CAD M1 phage probes (Davidson et al., 1990) which were a kind gift of Dr Thea Tlsty. The slides were warmed to room temperature in closed boxes and treated with RNAse (100 mg/ml) for 1 h at 378C. They were then ®xed with 4% paraformaldehyde and 1% methanol in 16PBS at 48C for 30 min, before they were dehydrated by passage through an ethanol series (75%, 85%, 100%) and air dried. Afterwards, 10 ± 20 ml of the hybridization mixture, containing 50 ± 55% deionized formamide (Merck), 10% dextran sulfate (Pharmacia AB, Sweden), 0.3 mg/ml sonicated DNA (salmon sperm DNA [Sigma] was used for the human chromosomes, total rat DNA for the rat chromosomes), 0.4 ± 0.8 mg/ml of the biotinylated CAD-DNA (labeled using the Bio Nick Labeling System of Gibco-BRL), all in 206SSC (3 M NaCl, 0.3 M sodium citrate, pH 7) was applied to each slide. This was covered with a 24650 mm cover slip, and sealed with ®xogum rubber cement (Marabou). Denaturation of the DNA was performed at 808C to 858C for 12 min on a heating plate, and hybridization was carried out overnight at 378C in a humidi®ed chamber. Following this, the preparations were washed in 50% formamide in 26SSC for 15 min at 378C. After a single wash (3 min) with 16PBS/0.1% Triton X-100, and three to ®ve washing steps in 16PBS for 5 min each, immunocytochemical detection of the biotinylated probe was carried out. For single target FISH, incubation was done consecutively with mouse anti-biotin (1:20 DAKO), rabbit anti mouse-FITC (1:100, DAKO) and swine anti rabbit-FITC (1:100 DAKO) for 40 ± 60 min each at 378C. All antibodies were diluted in 3% bovine serum albumin-16PBS. After each incubation step, the slides were washed in 0.1% bovine serum albumin-16PBS. For uorescence microscopy the slides were counter stained with DAPI (2 mg/ml), containing 4% paraformaldehyde and 1% methanol in 16PBS for 15 min. The slides were then washed with deionized water, air dried and mounted with Vectashield mounting medium (Vector laboratories Inc.). Slides were examined with a Zeiss Axioplan microscope, equipped with ®lter blocks for DAPI and FITC. Imaging was performed using a Smart Capture system (Visys) in combination with the Photometrix CCD camera.
